Exposure of the yeast Candida albicans to the anti‐neoplastic agent adriamycin increases the tolerance to amphotericin B

  title={Exposure of the yeast Candida albicans to the anti‐neoplastic agent adriamycin increases the tolerance to amphotericin B},
  author={Joseph O'Keeffe and Sean Doyle and Kevin Kavanagh},
  journal={Journal of Pharmacy and Pharmacology},
Cancer patients experience a high incidence of fungal infections due to their immuno‐suppressed condition. This work has investigated the interaction of an anti‐neoplastic agent, adriamycin (doxorubicin), with the yeast Candida albicans and examined whether this drug altered the susceptibility of the yeast to amphotericin B – an anti‐fungal agent used for the treatment of systemic fungal infections in cancer patients. Exposure to adriamycin for 24 h increased the growth of C. albicans and… 
Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species
Inhibition of candidal heat shock protein 90 and candidal-specific histone deacetylase represent feasible therapeutic approaches for candidiasis and the correlation of in vitro effects with clinically meaningful in vivo systems is warranted.
Anticancer drugs as enhancers of fluconazole sensitivity in Candida albicans
In vitro study, for the first time reveals efficacy of the thirty anticancer drugs to act as sensitizers in C. albicans, indicating that ability to sensitize C.Albicans towards fluconazole was not confined to a specific group.
Tolerance to amphotericin B in clinical isolates of Candida tropicalis.
The authors' data revealed a variable pattern of tolerance to amphotericin B among isolates of Candida tropicalis and showed that this phenomenon might influence the rate of organ clearance during therapy.
Development of a new real-time TaqMan PCR assay for quantitative analyses of Candida albicans resistance genes expression.
This work gives a short report on a real-time PCR (TaqMan) assay, which can be used for quantitative analyses of gene expression levels of MDR1, CDR1 and ERG11, genes supposed to contribute to development of the resistance mechanisms.
Antimicrobial natural products
This chapter has primarily focused into antimicrobial compounds developed through natural routes that are currently available as antibiotics for clinical uses and/or are at various developmental stages within the drug development pipeline for potential treatment of minor and life threatening infections.
Preparation, characterization and toxicity evaluation of amphotericin B loaded MPEG-PCL micelles and its application for buccal tablets
It is found that micelles system could significantly improve the solubility of AMB yet reduce the overall toxicity, while the buccal tablet system is capable to suppress C. albicans biofilm formation.
Molecular simulation of a modified amphotericin B-Ergosterol artificial water channel to evaluate structure and water molecule transport performance
Abstract Molecular simulation was adopted to investigate and compare the water-channel performance of a common Amphotericin B_Ergosterol (AmBEr) model with that of two hydrophobically modified
An inexpensive and easy-to-make customized antibiotics mix for mycobacterium culture
A customized antibiotics mix is presented that is easy to prepare at a fraction of the cost of the commercially available antibiotic mixture that protects against transient flora, which are normally present in lungs, without affecting mycobacterial colony number.


Antifungal drug resistance in pathogenic fungi.
In azole-resistant C. albicans isolates from AIDS patients with oropharyngeal candidiasis, multidrug efflux transporters of the ATP-binding cassette (ABC) superfamily and of the class of major facilitators (MF) have been shown to be responsible for the low level of accumulation of azole antifungal agents.
Candida and Aspergillus infections in immunocompromised patients: an overview.
  • R. Saral
  • Medicine
    Reviews of infectious diseases
  • 1991
More active, less toxic antifungal agents are needed to improve the efficacy of treatment and prophylaxis of disseminated fungal infection.
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell.
Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturation
It is shown in two clinical isolates that resistance was caused by defective sterol Δ5,6‐desaturation and growth arrest after fluconazole treatment of C. albicans in clinical conditions is caused by 14α‐methylergosta‐8,24(28)‐dien‐3β,6α‐diol accumulation.
Amphotericin B: an update.
  • K. Abu-Salah
  • Chemistry, Medicine
    British journal of biomedical science
  • 1996
This review highlights some important aspects of the physicochemical properties of amphotericin B and their utilisation in its quantitative determination in biological fluids and attempts to reduce its toxic effects to host cells and to improve its therapeutic index.
Practical modalities for prevention of fungal infections in cancer patients
  • B. D. Pauw
  • Medicine
    European Journal of Clinical Microbiology and Infectious Diseases
  • 2005
While the lack of data justifies a wait-and-see approach in patients at low or moderate risk of developing a fungal infection, it seems reasonable to administer prophylaxis to high-risk patients, even though there is presently no single agent suitable for all prophYLactic purposes.
Characterization of the mitochondrial respiratory pathways in Candida albicans.
Comparison of antifungal susceptibility of C. albicans cells respiring via the conventional or alternative respiratory pathways showed that respiration via the alternative pathway does not reduce the susceptibility of cells to a series of clinically employed antimycotics, or to the naturally occurring human salivary antIFungal peptide.
Nosocomial fungal infections: candidemia.
Candida species are frequently encountered as part of the human commensal flora and are associated with a high mortality and prolonged hospitalization, and because of the high frequency of dissemination, all candidemias should be treated.
Amphotericin B: new life for an old drug.
The recent leaps in pharmaceutics, spectrum and molecular mechanistic knowledge of amphotericin B are summarized to include select virus, parasite and possibly prion infections and a surprising expansion of the antibiotic spectrum of this surprising molecule.
Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study.
Fungal colonization profiles from four different anatomical sites were evaluated in 266 neutropenic cancer patients receiving intensive cytotoxic therapy for acute leukaemia or for autologous marrow transplantation, and fluconazole prophylaxis decreased colonization by fungi and subsequent invasive fungal infections in neutropetic cancer patients.